Hansa Biopharma AB (publ) (HNSBF) News Today → AI “wealth window” is closing soon! (From Paradigm Press) (Ad) Free HNSBF Stock Alerts $2.93 0.00 (0.00%) (As of 04/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWhat Wall Street expects from Hansa Medical AB's earningsmarkets.businessinsider.com - April 17 at 2:34 PMXbrane Biopharma AB XBRANEmorningstar.com - April 2 at 11:07 PMHansa Biopharma Expects Strong First Quarter 2024 Sales Performanceprnewswire.com - April 2 at 1:32 AMHansa Biopharma publishes 2023 Annual and Sustainability Reportsfinance.yahoo.com - March 21 at 2:44 AMEvan Ballantyne to join Hansa Biopharma as Chief Financial Officerprnewswire.com - February 22 at 9:24 AMHansa Biopharma AB (publ) 2023 Q4 - Results - Earnings Call Presentationseekingalpha.com - February 6 at 1:17 PMHansa Medical AB earnings: here's what to expectmarkets.businessinsider.com - February 1 at 1:31 PMHansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conferencefinance.yahoo.com - January 6 at 9:40 AMHansa Biopharma AB HNSAmorningstar.com - December 16 at 6:13 PMImlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantationfinance.yahoo.com - December 14 at 8:32 PMImlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)finance.yahoo.com - December 7 at 4:04 AMUpdate on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patientsfinance.yahoo.com - October 13 at 9:37 AMHansa Biopharma AB: Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patientsfinanznachrichten.de - October 11 at 3:09 PMHansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487finance.yahoo.com - October 9 at 2:44 PMDr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharmafinance.yahoo.com - September 1 at 9:01 AMHansa Biopharma half year report 2023finance.yahoo.com - July 20 at 7:39 AMFirst patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitisfinance.yahoo.com - July 19 at 10:16 AMIdefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantationfinance.yahoo.com - July 11 at 8:17 AMHansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Updatebenzinga.com - July 6 at 7:31 AMHansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financialsfinance.yahoo.com - July 4 at 7:37 AMHansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantationfinance.yahoo.com - June 1 at 2:20 AMHansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) diseasefinance.yahoo.com - May 30 at 4:01 AMHansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodiesfinance.yahoo.com - April 27 at 1:41 PMHansa Biopharma provides Q1 updatemsn.com - April 20 at 8:08 AMHansa Biopharma interim report January-March 2023finance.yahoo.com - April 20 at 3:07 AMHansa Biopharma AB (publ) (0RC7.IL)ca.finance.yahoo.com - March 30 at 1:37 PMHansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantationfinance.yahoo.com - March 29 at 12:32 PMMatthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharmafinance.yahoo.com - March 3 at 4:58 AMHansa Biopharma AB (publ) (HNSA.ST)finance.yahoo.com - February 10 at 1:13 PMHansa Biopharma Year-end report January-December 2022finance.yahoo.com - February 2 at 7:57 AMHansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republicfinance.yahoo.com - January 2 at 9:39 AMHansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantationfinance.yahoo.com - December 8 at 7:01 AMHansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantationfinance.yahoo.com - November 28 at 8:11 PMHansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta's SRP-9001 gene therapy in DMD in 2023finance.yahoo.com - November 3 at 2:42 AMHansa Biopharma Interim report January-September 2022finance.yahoo.com - October 20 at 3:54 AMHansa Biopharma: Increase of the number of shares and votesfinance.yahoo.com - September 30 at 4:22 PMHansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Updatefinance.yahoo.com - September 30 at 6:21 AMUBX Unity Biotechnology, Inc.seekingalpha.com - September 20 at 8:57 PMThe Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patientsfinance.yahoo.com - September 12 at 10:36 AMHansa Biopharma: Issue and repurchase of class C shares for incentive programsfinance.yahoo.com - September 9 at 4:25 PMHansa Biopharma and Medison Pharma announce positive reimbursement decision in Poland for Idefirix® in highly sensitized kidney transplant patientsfinance.yahoo.com - August 22 at 1:07 PMEuropean Society for Organ Transplantation's (ESOT) guidelines for desensitization treatment of highly sensitized kidney transplant patients published in Transplant Internationalfinance.yahoo.com - August 10 at 4:10 AMHere's what to expect from Hansa Medical AB's earningsmarkets.businessinsider.com - July 19 at 3:24 AMHansa Biopharma half year report 2022finance.yahoo.com - July 19 at 3:24 AMHansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest to support continued development of the company's antibody-cleaving enzyme technology platformfinance.yahoo.com - July 18 at 5:20 PMHansa Biopharma announces first patient treated in the post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patientsfinance.yahoo.com - July 11 at 5:04 AMThe FDA accepts BLA and grants priority review for lecanemab for treatment of early Alzheimer's disease under the accelerated approval pathwayyahoo.com - July 6 at 2:01 AMNICE recommends use of Hansa Biopharma's Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patientsfinance.yahoo.com - June 16 at 4:52 AMHansa Biopharma AB's (HNSBF) CEO Søren Tulstrup on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - April 21 at 6:34 PMHansa Biopharma interim report January - March 2022finance.yahoo.com - April 21 at 8:34 AM Get Hansa Biopharma AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for HNSBF and its competitors with MarketBeat's FREE daily newsletter. Email Address AI “wealth window” is closing soon! (Ad)Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry. I put together this personal video [HERE]… HNSBF Media Mentions By Week HNSBF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HNSBF News Sentiment▼0.000.40▲Average Medical News Sentiment HNSBF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HNSBF Articles This Week▼10▲HNSBF Articles Average Week Get Hansa Biopharma AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for HNSBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ARTLW News Today ASCLF News Today AWKNF News Today AXIM News Today BRRGF News Today BCTXW News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:HNSBF) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hansa Biopharma AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.